

Reference number(s)
2217-H

SPECIALTY QUANTITY LIMIT PROGRAM

VOTRIENT (pazopanib HCl)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Votrient (pazopanib HCl) tablet 200 mg	120 per 30 days	800 mg once daily

III. REFERENCES

- Votrient [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2017.